Genervon Biopharmaceuticals looks to the pharmaceutical industry to deliver its neurodegenerative drug to market

March 23, 2018 - Biotech Capital

Genervon is on the lookout for pharma partners to help advance its GM6 drug, which takes aim at a range of deadly diseases hitting the central nervous system

Read Article


Genervon Continues to Focus on Nerve Cell Development Factor as ALS Treatment

March 5, 2018 - ALS News Today

Genervon Biopharmaceuticals says its efforts to develop treatments for ALS and other neurodegenerative diseases continue to focus on a factor that regulates stem cells’ evolution into nerve cells.

It continues working on Phase 3 clinical trial plans, it added.

The company outlined its treatment-development strategy at the 2018 BIO CEO & Investor Conference in New York City in February.

Read Article


VICE on HBO: Debrief on Living with ALS

One of the patients treated with GM6 under a compassionate use application is a journalist who works for VICE Media. VICE produced a video for HBO, “Debrief on Living with ALS,” in which the patient reported that GM6 helped stop her disease progression for the 6 months following her last dose. 


VICE ALS Episode: Die Trying